Bortenat injection (Bortezomib) is used to treat multiple myeloma and mantle cell lymphoma.
Bortenat (Bortezomib) is sometimes given after other cancer medications have been tried without successful treatment.
Bortenat (Bortezomib injection) is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The active site of the proteasome has chymotrypsin-like, trypsin-like, and postglutamyl peptide hydrolysis activity. The 26S proteasome degrades various proteins critical to cancer cell survival, such as cyclins, tumor suppressors, BCL-2, and cyclin-dependent kinase inhibitors. Inhibition of these degradations sensitizes cells to apoptosis. Bortenat injection is a potent inhibitor of 26S proteasome, which sensitizes activity in dividing multiple myeloma and leukemic cells, thus inducing apoptosis.
Use Bortenat (Bortezomib) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; diarrhea; dizziness; headache; loss of appetite; mild stomach pain; nausea; stomach upset; taste changes; tiredness; trouble sleeping; vomiting; weakness.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing .Keep out of the reach of children. Do not keep outdated medicine or medicine no longer needed.
Bortenat is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
Bortecad (Bortezomib) is used to treat multiple myeloma and mantle cell lymphoma.
Bortecad (Bortezomib) is sometimes given after other cancer medications have been tried without successful treatment.
Bortecad (Bortezomib) is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The active site of the proteasome has chymotrypsin-like, trypsin-like, and postglutamyl peptide hydrolysis activity. The 26S proteasome degrades various proteins critical to cancer cell survival, such as cyclins, tumor suppressors, BCL-2, and cyclin-dependent kinase inhibitors. Inhibition of these degradations sensitizes cells to apoptosis. Bortecad (Bortezomib) is a potent inhibitor of 26S proteasome, which sensitizes activity in dividing multiple myeloma and leukemic cells, thus inducing apoptosis.
Use Bortecad (Bortezomib) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; diarrhea; dizziness; headache; loss of appetite; mild stomach pain; nausea; stomach upset; taste changes; tiredness; trouble sleeping; vomiting; weakness.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing .Keep out of the reach of children. Do not keep outdated medicine or medicine no longer needed.
Bortecad is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
Myezom (Bortezomib) is used to treat multiple myeloma and mantle cell lymphoma.
Myezom (Bortezomib) is sometimes given after other cancer medications have been tried without successful treatment.
Myezom (Bortezomib) is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The active site of the proteasome has chymotrypsin-like, trypsin-like, and postglutamyl peptide hydrolysis activity. The 26S proteasome degrades various proteins critical to cancer cell survival, such as cyclins, tumor suppressors, BCL-2, and cyclin-dependent kinase inhibitors. Inhibition of these degradations sensitizes cells to apoptosis. Myezom (Bortezomib) is a potent inhibitor of 26S proteasome, which sensitizes activity in dividing multiple myeloma and leukemic cells, thus inducing apoptosis
Use Myezom (Bortezomib) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; diarrhea; dizziness; headache; loss of appetite; mild stomach pain; nausea; stomach upset; taste changes; tiredness; trouble sleeping; vomiting; weakness.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing .Keep out of the reach of children. Do not keep outdated medicine or medicine no longer needed.
Myezom is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
Velcade (Bortezomib) is used to treat multiple myeloma and mantle cell lymphoma.
Velcade (Bortezomib) is sometimes given after other cancer medications have been tried without successful treatment.
Velcade (Bortezomib) is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The active site of the proteasome has chymotrypsin-like, trypsin-like, and postglutamyl peptide hydrolysis activity. The 26S proteasome degrades various proteins critical to cancer cell survival, such as cyclins, tumor suppressors, BCL-2, and cyclin-dependent kinase inhibitors. Inhibition of these degradations sensitizes cells to apoptosis. Velcade (Bortezomib) is a potent inhibitor of 26S proteasome, which sensitizes activity in dividing multiple myeloma and leukemic cells, thus inducing apoptosis
Use Velcade (Bortezomib) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; diarrhea; dizziness; headache; loss of appetite; mild stomach pain; nausea; stomach upset; taste changes; tiredness; trouble sleeping; vomiting; weakness.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing .Keep out of the reach of children. Do not keep outdated medicine or medicine no longer needed.
Velcade is a prescription drug and should be used under proper medical guidance and advice. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.